Results 131 to 140 of about 6,340 (200)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. [PDF]

Front Pharmacol, 2022
Li S, Zhuge A, Wang K, Xia J, Wang Q, Han S, Shen J, Li L.   +7 more
europepmc   +1 more source

Pharmaco-nutraceutical improvement of the response to obeticholic acid with omega-3 polyunsaturated fatty acids. [PDF]

Biochem J
Lavoie AA, Thérien A, Silva A, Paré E, Ciešlak A, Gagnon W, Desjardins C, Verreault M, Trottier J, Vohl MC, Drouin-Chartier JP, Corbeil J, Caron A, Barbier O.   +13 more
europepmc   +1 more source

Structure-Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off-Target Effects. [PDF]

ChemMedChem
Passeri D, Cerra B, Carotti A, Greco F, Piermarini S, Colliva C, Liscio P, De Franco F, Adorini L, Erickson MR, Pellicciari R, Gioiello A.   +11 more
europepmc   +1 more source

Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice. [PDF]

Redox Biol, 2023
Zhuge A, Li S, Yuan Y, Han S, Xia J, Wang Q, Wang S, Lou P, Li B, Li L.   +9 more
europepmc   +1 more source

Von der Pathophysiologie zur Therapie chronisch cholestatischer Lebererkrankungen [PDF]

, 2017
Hohenester, Simon
core  

Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor. [PDF]

Biomedicines
Jamal F, Elshaer A, Alatout MH, Odeh NB, Youssef A, Abo Abdullah H, Elmasry S, Shahin T, Abdul Nabi H, Worden AR, Malik TA, Lizaola-Mayo BC.   +11 more
europepmc   +1 more source

Correction: Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand. [PDF]

Cancer Gene Ther, 2022
Yu J, Yang K, Zheng J, Zhao W, Sun X.
europepmc   +1 more source

Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome [PDF]

, 2016

core   +1 more source

Cost-effectiveness of obeticholic acid for the treatment of non-alcoholic steatohepatitis: An early economic evaluation. [PDF]

Can Liver J, 2021
Tran CP, Kim JJ, Feld JJ, Wong WW.
europepmc   +1 more source

Hepatic angiosarcoma in a patient treated with obeticholic acid for primary biliary cholangitis. [PDF]

Hepatol Forum
Arif AA, Punnen S, Bleszynski M, Daniel R O, Yoshida EM.   +4 more
europepmc   +1 more source